Links
-
New Genetic Regulators Could Improve Cancer Immunotherapy
A genetic screen has revealed previously unknown regulators of Foxp3, a transcription factor that, when deactivated, may improve patient response to aggressive cancers.
-
First Trial Shows Benefit for Genomically Targeted Prostate Cancer Treatment
For the first time, advanced prostate cancer has been treated based on the genomic makeup of the cancer, delaying disease progression for patients with a treatment-resistant form of prostate cancer
-
Uncovering the Cellular Mechanisms Behind Genetic Mutations in ALS
Northwestern Medicine scientists have discovered that mutations in the largest genetic contributor to ALS leads to the dysfunction and eventual degeneration of certain specialized subtypes in the brain. The findings may lead to development of novel therapeutic interventions for the disease.
-
New Migration of Brain Tumor Discovered
A previously unknown migration of glioblastoma may explain why current treatments stall out over time, according to a new stu
-
‘Soft’ Symptoms Detected Before Parkinson’s Disease
People who carry genetic mutations associated with an increased risk for Parkinson’s disease may exhibit minor symptoms long before the disease progresses to affect daily life, according to a study of over 300 patients.
-
Total Heart Disease Deaths on The Rise
Total deaths from heart disease, stroke, diabetes and hypertension have been increasing since 2011, according to a new Northwestern Medicine study.
-
Newly Discovered Mechanism May Control Inflammation
A new study has discovered previously unknown details about a mechanism that lets white blood cells travel from blood vessels into tissue, a process key to inflammation.
-
Sesame Allergy More Common Than Previously Recognized
Sesame allergy affects more than 1 million children and adults in the U.S., more than previously known, according to a new Northwestern Medicine study.
-
New Insights Into Role of RNA Methylation in Fragile X Syndrome
Northwestern Medicine scientists have discovered that the protein FMRP — the loss of which leads to Fragile X syndrome — is a novel reader of RNA methylation.
-
Key Findings in Cancer Care for Women
Results from a randomized phase 3 clinical trial published in The New England Journal of Medicine could change the way women are treated for later stage endometrial cancer. Northwestern’s Daniela Matei, MD, led the trial and shares the details.